Although technically not a p53 gene delivery strategy, a more recently CRISPR/Cas9-based therapeutic vector (inducible and tumour specific) has been proposed to restore p53 function in mutp53 cells [150,151]. This evidence concerns the gene TP53 and neoplasm.